Menu Search
Equities

Pacific Biosciences of California Inc

PACB:NSQ

Pacific Biosciences of California Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.77
  • Today's Change0.05 / 2.91%
  • Shares traded8.05m
  • 1 Year change-78.62%
  • Beta1.9647
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform4
Hold9
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Pacific Biosciences of California Inc have a median target of 2.50, with a high estimate of 6.00 and a low estimate of 1.00. The median estimate represents a 41.24% increase from the last price of 1.77.
High239.0%6.00
Med41.2%2.50
Low-43.5%1.00

Earnings history & estimates in USD

On Nov 07, 2024, Pacific Biosciences of California Inc reported 3rd quarter 2024 losses of -0.22 per share. This result was in line with the consensus of the 12 analysts following the company and exceeded last year's 3rd quarter results by 15.38%.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate-16.96%
Pacific Biosciences of California Inc reported annual 2023 losses of -1.21 per share on Feb 15, 2024.
Average growth rate-22.76%
More ▼

Revenue history & estimates in USD

Pacific Biosciences of California, Inc. had 3rd quarter 2024 revenues of 39.97m. This missed the 41.96m consensus estimate of the 13 analysts following the company. This was 2.74% above the prior year's 3rd quarter results.
Average growth rate-6.23%
Pacific Biosciences of California, Inc. had revenues for the full year 2023 of 200.52m. This was 56.29% above the prior year's results.
Average growth rate+26.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.